FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma By Ogkologos - July 18, 2025 657 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the KEYNOTE-689 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR How clues from crystals might help us prevent the overtreatment of... June 20, 2023 FDA Grants Accelerated Approval to Futibatinib for Cholangiocarcinoma October 6, 2022 Incidence, Relative Risk and Risk Factors for Chronic Comorbidities in Long-Term... July 22, 2020 Dexrazoxane Protects the Heart Long Term for Kids Being Treated for... March 16, 2023 Load more HOT NEWS New Combination of Old Drugs Improves Survival in Patients with Prostate... ESMO Sarcoma & GIST Symposium 2022, 31 January – 2 February Cancer Survivor Kicked Out Of Bridal Party Cause She Refused To... No OS Benefit for Active Maintenance Treatment with Olaparib Relative to...
